🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fernando A. Angarita

Methodist Hospital

ORCID: 0000-0002-8546-7309
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.359Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.561
Top 49%
0.359DataRank
Top 49%5 citations

Lan Le, Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama +3 more

Papers

Driven by 6 papers — median percentile 51. Top paper: “Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).”.

Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.561
Top 49%
0.359DataRank
Top 49%5 citations

Lan Le, Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama +3 more

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Cancers(2020)10.3390/cancers12103038
N/A
0DataRank · unranked
106 citations

Mariko Asaoka, Yoshihisa Tokumaru, Fernando A. Angarita, Li Yan, Ryusei Matsuyama +5 more

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer

Cancers(2020)10.3390/cancers12123557
N/A
0DataRank · unranked
56 citations

Yoshihisa Tokumaru, Fernando A. Angarita, Li Yan, Ryusei Matsuyama, Itaru Endo +2 more

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer

Cancers(2020)10.3390/cancers12123856
N/A
0DataRank · unranked
42 citations

Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo +2 more

Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival

Scientific Reports(2021)10.1038/s41598-021-91897-7
N/A
0DataRank · unranked
54 citations

Yoshihisa Tokumaru, Fernando A. Angarita, Lan Lee, Li Yan, Ryusei Matsuyama +3 more

De-Escalating the Management of In Situ and Invasive Breast Cancer

Cancers(2022)10.3390/cancers14194545
N/A
0DataRank · unranked
19 citations

Robert Brumer, Matthew Castelo, Nestor F. Esnaola, Stephen B. Edge, Kazuaki Takabe +1 more